Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection

Anthony M Casapao1, Steven N Leonard2, Susan L Davis1,3

  • 1Anti-Infective Research Laboratory, Pharmacy Practice Department, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Insights

Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infections lead to significantly higher vancomycin treatment failure rates compared to vancomycin-susceptible Staphylococcus aureus (VSSA). This highlights hVISA as a major cause of morbidity in MRSA infections.

Area of Science:

  • Infectious Diseases
  • Clinical Microbiology
  • Pharmacology

Background:

  • Prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections is unclear due to lack of routine screening.
  • Limited data suggest hVISA is associated with persistent bloodstream infections (BSI) and vancomycin treatment failure.
  • Previous studies on hVISA outcomes are confounded by design limitations.

Purpose of the Study:

  • To compare clinical characteristics and outcomes of patients with hVISA BSI versus vancomycin-susceptible Staphylococcus aureus (VSSA) BSI.
  • To evaluate vancomycin treatment failure rates in patients with hVISA compared to VSSA.

Main Methods:

  • Retrospective, multicenter, matched (1:1) cohort study.
  • Compared patients with hVISA methicillin-resistant Staphylococcus aureus (MRSA) BSI (2004-2012) to VSSA-MRSA BSI patients.
  • Primary outcome: vancomycin treatment failure (persistent bacteremia, persistent signs/symptoms, antibiotic change, recurrent BSI, or MRSA-related mortality).

Main Results:

  • Overall vancomycin failure rate was 57% (82% in hVISA vs. 33% in VSSA; P < 0.001).
  • hVISA was associated with significantly higher rates of persistent bacteremia (59% vs. 21%), change in MRSA therapy (54% vs. 25%), and recurrent BSI (26% vs. 2%).
  • hVISA (aOR, 11.1) and ICU admission (aOR, 4.5) were independently associated with vancomycin failure.

Conclusions:

  • Patients with hVISA BSI are significantly more likely to experience vancomycin treatment failure compared to VSSA BSI.
  • hVISA infections contribute to substantial patient morbidity, including persistent bacteremia and recurrent infections.
  • The findings underscore the clinical significance of hVISA and the need for improved diagnostic and treatment strategies.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...